PL3515938T3 - Przeciwciała monoklonalne przeciwko programowanej śmierci 1 (pd‑1) - Google Patents
Przeciwciała monoklonalne przeciwko programowanej śmierci 1 (pd‑1)Info
- Publication number
- PL3515938T3 PL3515938T3 PL16916449.8T PL16916449T PL3515938T3 PL 3515938 T3 PL3515938 T3 PL 3515938T3 PL 16916449 T PL16916449 T PL 16916449T PL 3515938 T3 PL3515938 T3 PL 3515938T3
- Authority
- PL
- Poland
- Prior art keywords
- monoclonal antibodies
- programmed death
- death
- programmed
- monoclonal
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2806—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2016/099576 WO2018053709A1 (en) | 2016-09-21 | 2016-09-21 | The novel monoclonal antibodies to programmed death 1 (pd-1) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3515938T3 true PL3515938T3 (pl) | 2025-06-09 |
Family
ID=61690082
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL16916449.8T PL3515938T3 (pl) | 2016-09-21 | 2016-09-21 | Przeciwciała monoklonalne przeciwko programowanej śmierci 1 (pd‑1) |
Country Status (23)
| Country | Link |
|---|---|
| US (3) | US11414487B2 (pl) |
| EP (2) | EP4450616A3 (pl) |
| JP (2) | JP7101169B2 (pl) |
| KR (2) | KR102527160B1 (pl) |
| AU (1) | AU2016423559C1 (pl) |
| BR (1) | BR112019005316A2 (pl) |
| CA (1) | CA3037407C (pl) |
| DK (1) | DK3515938T3 (pl) |
| ES (1) | ES3017957T3 (pl) |
| FI (1) | FI3515938T3 (pl) |
| HR (1) | HRP20250400T1 (pl) |
| HU (1) | HUE071253T2 (pl) |
| IL (1) | IL265525A (pl) |
| LT (1) | LT3515938T (pl) |
| MX (1) | MX2019003058A (pl) |
| PL (1) | PL3515938T3 (pl) |
| PT (1) | PT3515938T (pl) |
| RS (1) | RS66679B1 (pl) |
| RU (1) | RU2757316C2 (pl) |
| SA (1) | SA519401370B1 (pl) |
| SI (1) | SI3515938T1 (pl) |
| SM (1) | SMT202500148T1 (pl) |
| WO (1) | WO2018053709A1 (pl) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY187739A (en) | 2015-08-11 | 2021-10-18 | Wuxi Biologics Cayman Inc | Novel anti-pd-1 antibodies |
| SMT202200118T1 (it) | 2015-11-03 | 2022-05-12 | Janssen Biotech Inc | Anticorpi che legano specificamente pd-1 e loro usi |
| LT3515938T (lt) * | 2016-09-21 | 2025-05-12 | Cstone Pharmaceuticals | Monokloniniai antikūnai prieš programuojamą mirtį 1 (pd-1) |
| HRP20211703T1 (hr) | 2016-11-02 | 2022-02-04 | Jounce Therapeutics, Inc. | Protutijela protiv pd-1 i njihova upotreba |
| ES2910969T3 (es) | 2017-08-03 | 2022-05-17 | Amgen Inc | Muteínas de interleucina-21 y métodos de tratamiento |
| TW201930344A (zh) | 2018-01-12 | 2019-08-01 | 美商安進公司 | 抗ｐｄ-１抗體及治療方法 |
| US12398209B2 (en) | 2018-01-22 | 2025-08-26 | Janssen Biotech, Inc. | Methods of treating cancers with antagonistic anti-PD-1 antibodies |
| JP7054573B2 (ja) * | 2018-04-15 | 2022-04-14 | イムヴィラ・カンパニー・リミテッド | Ｐｄ－１結合抗体及びその用途 |
| KR20200143689A (ko) * | 2018-04-15 | 2020-12-24 | 살루브리스 (청두) 바이오테크 코., 리미티드 | Pd-1 결합 항체 및 그의 용도 |
| CN109160949B (zh) * | 2018-07-23 | 2021-05-14 | 中国医学科学院血液病医院（血液学研究所） | 一种鼠抗人pd-1单克隆抗体及应用 |
| WO2020216348A1 (en) * | 2019-04-26 | 2020-10-29 | Wuxi Biologics (Shanghai) Co., Ltd. | Bispecific antibodies against pd-1 and lag-3 |
| CN113874036A (zh) | 2019-05-24 | 2021-12-31 | 辉瑞公司 | 使用cdk抑制剂的联合治疗 |
| WO2021057836A1 (en) * | 2019-09-25 | 2021-04-01 | Wuxi Biologics (Shanghai) Co. Ltd. | Novel anti-pd-l1 antibodies |
| JP2023500385A (ja) * | 2019-11-11 | 2023-01-05 | シーストーン・ファーマシューティカルズ・（スージョウ）・カンパニー・リミテッド | 医薬組合せ物およびその使用 |
| WO2021110122A1 (zh) * | 2019-12-05 | 2021-06-10 | 基石药业（苏州）有限公司 | Cdk4/6抑制剂的组合疗法 |
| PH12022553181A1 (en) | 2020-05-26 | 2024-03-04 | Boehringer Ingelheim Int | Anti-pd-1 antibodies |
| AU2021330087B2 (en) * | 2020-08-31 | 2025-10-23 | Biosion Inc. | PD-1 binding antibodies and uses thereof |
| CN114316022A (zh) * | 2020-09-30 | 2022-04-12 | 正大天晴康方(上海)生物医药科技有限公司 | 结合pd-1抗体的肽及其应用 |
| US20220168293A1 (en) | 2020-12-02 | 2022-06-02 | Pfizer Inc. | Time to resolution of axitinib-related adverse events |
| KR102661163B1 (ko) * | 2021-02-04 | 2024-04-26 | 주식회사 지뉴브 | 항 pd-1 항체 및 그의 용도 |
| TW202327595A (zh) | 2021-10-05 | 2023-07-16 | 美商輝瑞大藥廠 | 用於治療癌症之氮雜內醯胺化合物的組合 |
| WO2023079428A1 (en) | 2021-11-03 | 2023-05-11 | Pfizer Inc. | Combination therapies using tlr7/8 agonist |
| CN116036266A (zh) * | 2022-12-28 | 2023-05-02 | 广州誉衡生物科技有限公司 | 抗-pd-1抗体及其在制备治疗结肠癌患者的药物中的用途 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090123413A1 (en) | 2004-08-23 | 2009-05-14 | Britta Hardy | Use of bat monoclonal antibody for immunotherapy |
| ES2720160T3 (es) | 2005-05-09 | 2019-07-18 | Ono Pharmaceutical Co | Anticuerpos monoclonales humanos contra muerte programada 1(PD-1) y métodos para tratar el cáncer usando anticuerpos dirigidos contra PD-1 solos o junto con otras sustancias inmunoterapéuticas |
| US7662965B2 (en) * | 2006-01-26 | 2010-02-16 | Cornerstone Therapeutics, Inc. | Anabaseine derivatives, pharmaceutical compositions and method of use thereof |
| EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
| AU2013240281B2 (en) * | 2012-03-30 | 2017-12-21 | Eisai R&D Management Co., Ltd. | TEM-1 diagnostic antibodies |
| ES2716685T3 (es) * | 2014-01-24 | 2019-06-14 | Dana Farber Cancer Inst Inc | Moléculas de anticuerpo para PD-1 y usos de las mismas |
| CN105330740B (zh) | 2014-07-30 | 2018-08-17 | 珠海市丽珠单抗生物技术有限公司 | 抗pd-1抗体及其应用 |
| US10822414B2 (en) * | 2014-11-11 | 2020-11-03 | Sutro Biopharma, Inc. | Anti-PD-1 antibodies, compositions comprising anti-PD-1 antibodies and methods of using anti-PD-1 antibodies |
| TWI595006B (zh) | 2014-12-09 | 2017-08-11 | 禮納特神經系統科學公司 | 抗ｐｄ－１抗體類和使用彼等之方法 |
| EA201791768A1 (ru) | 2015-02-06 | 2018-07-31 | КАДМОН КОРПОРЕЙШН, ЭлЭлСи | Иммуномодулирующие агенты |
| MY187739A (en) | 2015-08-11 | 2021-10-18 | Wuxi Biologics Cayman Inc | Novel anti-pd-1 antibodies |
| SG10201912943RA (en) | 2015-10-02 | 2020-02-27 | Symphogen As | Anti-pd-1 antibodies and compositions |
| LT3515938T (lt) * | 2016-09-21 | 2025-05-12 | Cstone Pharmaceuticals | Monokloniniai antikūnai prieš programuojamą mirtį 1 (pd-1) |
| WO2019062755A1 (en) * | 2017-09-29 | 2019-04-04 | Wuxi Biologics (Shanghai) Co., Ltd. | BISPECIFIC ANTIBODIES DIRECTED AGAINST EGFR AND PD-1 |
| JP2023500385A (ja) * | 2019-11-11 | 2023-01-05 | シーストーン・ファーマシューティカルズ・（スージョウ）・カンパニー・リミテッド | 医薬組合せ物およびその使用 |
-
2016
- 2016-09-21 LT LTEPPCT/CN2016/099576T patent/LT3515938T/lt unknown
- 2016-09-21 BR BR112019005316-6A patent/BR112019005316A2/pt active Search and Examination
- 2016-09-21 RS RS20250329A patent/RS66679B1/sr unknown
- 2016-09-21 SI SI201631893T patent/SI3515938T1/sl unknown
- 2016-09-21 HU HUE16916449A patent/HUE071253T2/hu unknown
- 2016-09-21 HR HRP20250400TT patent/HRP20250400T1/hr unknown
- 2016-09-21 FI FIEP16916449.8T patent/FI3515938T3/fi active
- 2016-09-21 KR KR1020217020495A patent/KR102527160B1/ko active Active
- 2016-09-21 CA CA3037407A patent/CA3037407C/en active Active
- 2016-09-21 MX MX2019003058A patent/MX2019003058A/es unknown
- 2016-09-21 EP EP24184760.7A patent/EP4450616A3/en active Pending
- 2016-09-21 AU AU2016423559A patent/AU2016423559C1/en active Active
- 2016-09-21 US US16/333,993 patent/US11414487B2/en active Active
- 2016-09-21 SM SM20250148T patent/SMT202500148T1/it unknown
- 2016-09-21 RU RU2019111277A patent/RU2757316C2/ru active
- 2016-09-21 DK DK16916449.8T patent/DK3515938T3/da active
- 2016-09-21 ES ES16916449T patent/ES3017957T3/es active Active
- 2016-09-21 WO PCT/CN2016/099576 patent/WO2018053709A1/en not_active Ceased
- 2016-09-21 JP JP2019515471A patent/JP7101169B2/ja active Active
- 2016-09-21 PT PT169164498T patent/PT3515938T/pt unknown
- 2016-09-21 PL PL16916449.8T patent/PL3515938T3/pl unknown
- 2016-09-21 EP EP16916449.8A patent/EP3515938B8/en active Active
- 2016-09-21 KR KR1020197010353A patent/KR102273634B1/ko active Active
-
2019
- 2019-03-20 SA SA519401370A patent/SA519401370B1/ar unknown
- 2019-03-20 IL IL265525A patent/IL265525A/en unknown
-
2021
- 2021-04-21 JP JP2021071948A patent/JP2021120378A/ja active Pending
-
2022
- 2022-06-29 US US17/853,606 patent/US20230014722A1/en not_active Abandoned
-
2023
- 2023-08-31 US US18/459,236 patent/US20240101676A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL265525A (en) | New monoclonal antibodies against pd-1 | |
| HUS2500002I1 (hu) | Újszerû anti-PD-L1 antitestek | |
| ZA201900353B (en) | Anti-pd-l1 antibodies | |
| IL261188A (en) | Antibodies against tigit | |
| IL262295A (en) | Antibodies against pd-l1 | |
| IL256922A (en) | Pd-l1 (" programmed death-ligand 1" ) antibodies | |
| IL266229A (en) | Antibodies directed against pd-1 | |
| IL255727A (en) | Novel anti-pd-l1 antibodies | |
| SG10201603721TA (en) | Anti-CTLA-4 Antibodies | |
| ZA201807167B (en) | Humanized anti-il-1r3 antibodies | |
| IL272911A (en) | Antibodies to programmed cell death protein 1 (PD-1) | |
| ZA201907065B (en) | Monoclonal antibody to pd-l1 | |
| PT3484446T (pt) | Composições de anticorpos | |
| EP3559044A4 (en) | IMMUNOTHERAPY USING ANTIBODIES THAT BINDING PROGRAMMED CELL DEATH 1 (PD-1) | |
| SMT202100185T1 (it) | Anticorpi umanizzati anti-cd28 formulati per somministrazione agli essere umani | |
| GB201609742D0 (en) | Improvements relating to antibodies | |
| GB201511196D0 (en) | Monoclonal antibodies | |
| GB201700210D0 (en) | Single domain antibodies to programmed cell death (PD-1) | |
| GB201700208D0 (en) | Single domain antibodies to programmed cell death (PD-1) | |
| PT3390450T (pt) | Anticorpos humanizados anti-cd28 formulados para administração a humanos | |
| HK40034252A (en) | Antibodies to programmed cell death protein 1 | |
| GB201621446D0 (en) | IL-11 antibodies | |
| GB201709535D0 (en) | IL-11 Antibodies |